Nephro-Urology Monthly

Published by: Kowsar

Comparison of the Efficacy of Tacrolimus Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

Hamidreza Omrani 1 , Sima Golmohamadi 1 , * , Fateme Hichi 2 and Masoud Sadeghi 3
Authors Information
1 Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3 Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Nephro-Urology Monthly: January 01, 2017, 9 (1); e42473
  • Published Online: November 14, 2016
  • Article Type: Research Article
  • Received: September 30, 2016
  • Accepted: November 6, 2016
  • DOI: 10.5812/numonthly.42473

To Cite: Omrani H, Golmohamadi S, Hichi F, Sadeghi M. Comparison of the Efficacy of Tacrolimus Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy, Nephro-Urol Mon. 2017 ; 9(1):e42473. doi: 10.5812/numonthly.42473.

Copyright © 2016, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Tryggvason K, Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med. 2003; 254(3): 216-24[PubMed]
  • 2. Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014; (10)[DOI][PubMed]
  • 3. Santosh T, Liu H, Liu B. Effect of tacrolimus in idiopathic membranous nephropathy: a meta-analysis. Chin Med J (Engl). 2014; 127(14): 2693-9[PubMed]
  • 4. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int. 2007; 72(12): 1429-47[DOI][PubMed]
  • 5. Yuan H, Liu N, Sun GD, Jia Y, Luo P, Miao LN. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology. 2013; 91(5-6): 259-66[DOI][PubMed]
  • 6. Tao JL, Liu LL, Wen YB, Gao RT, Li H, Li MX, et al. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years. Chin Med J (Engl). 2011; 124(21): 3490-4[PubMed]
  • 7. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59(4): 1484-90[DOI][PubMed]
  • 8. Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, et al. Cyclosporin A treatment for idiopathic membranous nephropathy. Chin Med J (Engl). 2001; 114(12): 1305-8[PubMed]
  • 9. Li X, Lv R, He Q, Li H, Du X, Lin W, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol. 2008; 21(4): 584-91[PubMed]
  • 10. Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007; 71(9): 924-30[DOI][PubMed]
  • 11. Ballarin J, Poveda R, Ara J, Perez L, Calero F, Grinyo JM, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant. 2007; 22(11): 3196-201[DOI][PubMed]
  • 12. Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3): 233-8[DOI][PubMed]
  • 13. Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015; 35(5): 623-8[DOI][PubMed]
  • 14. Caro J, Gutierrez-Solis E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 2015; 30(3): 467-74[DOI][PubMed]
  • 15. Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013; 181: 152-62[DOI][PubMed]
  • 16. Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. Biomed Pharmacother. 2011; 65(2): 105-10[DOI][PubMed]
  • 17. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006; 21(11): 3127-32[DOI][PubMed]
  • 18. du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study G. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant. 2004; 19(5): 1142-8[DOI][PubMed]
  • 19. du Buf-Vereijken PW, Feith GW, Hollander D, Gerlag PG, Wirtz JJ, Noordzij TC, et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM. 2004; 97(6): 353-60[PubMed]
  • 20. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol. 2007; 27(3): 226-31[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments